Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
JAK inhibitor
Biotech
Incyte posts phase 3 skin condition wins but details disappoint
With the response rate down on phase 2, the results drew unfavorable comparisons to rival data and triggered a 15% drop in the biotech’s share price.
Nick Paul Taylor
Mar 17, 2025 8:12am
Aclaris claims ph. 2 win for JAK inhibitor but investors spooked
Jan 10, 2024 8:35am
Lynk hits main goal to wrap up clean sweep of phase 2 JAK trials
Aug 23, 2023 9:55am
Sun's $576M Concert hits bum note as FDA imposes partial hold
May 2, 2023 7:09am
Minghui's phase 2 win for potential Opzelura competitor
Apr 14, 2023 10:35am
Galapagos cleans closet of another 4 programs in CAR-T pivot
Aug 5, 2022 10:03am
